When is crossover desirable in cancer drug trials and when is it problematic?

A. Haslam, Vinay Prasad

Research output: Contribution to journalEditorial

2 Citations (Scopus)
Original languageEnglish (US)
Number of pages1
JournalAnnals of Oncology
Volume29
Issue number5
DOIs
StatePublished - May 1 2018

Fingerprint

Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

When is crossover desirable in cancer drug trials and when is it problematic? / Haslam, A.; Prasad, Vinay.

In: Annals of Oncology, Vol. 29, No. 5, 01.05.2018.

Research output: Contribution to journalEditorial

@article{d096d232307e40968941beaaec411c48,
title = "When is crossover desirable in cancer drug trials and when is it problematic?",
author = "A. Haslam and Vinay Prasad",
year = "2018",
month = "5",
day = "1",
doi = "10.1093/annonc/mdy116",
language = "English (US)",
volume = "29",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - When is crossover desirable in cancer drug trials and when is it problematic?

AU - Haslam, A.

AU - Prasad, Vinay

PY - 2018/5/1

Y1 - 2018/5/1

UR - http://www.scopus.com/inward/record.url?scp=85047609411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047609411&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy116

DO - 10.1093/annonc/mdy116

M3 - Editorial

AN - SCOPUS:85047609411

VL - 29

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 5

ER -